A

Apellis Pharmaceuticals Tech Stack

Public biotech focused on C3 complement targeting across ophthalmology, nephrology, and hematology

Biotechnology Research Waltham, MA 501–1,000 employees Founded 2008 Public Company

Apellis is a public-stage biopharma company executing a multi-indication product launch strategy while managing significant operational scaling. The hiring mix is sales-heavy (16 active roles) paired with sustained finance and healthcare staffing, reflecting simultaneous commercial expansion and regulatory complexity. Active projects center on geographic-atrophy and retina-program launches, while pain points cluster around compliance standardization, process scalability during growth, and field-resource gaps—a profile consistent with a company transitioning from clinical-stage to multi-product commercial maturity.

Tech Stack 18 technologies

Core StackSAP SAS Workday SAP S/4HANA Adaptive Insights FMEA Veeva Microsoft Office SharePoint Workday Studio FloQast AuditBoard Concur Alteryx Outlook Word Excel Teams

What Apellis Pharmaceuticals Is Building

◆Challenges

Ensuring compliance and standardization
Launching first product in germany
Process scalability
Security audits and compliance
Upgrades and migrations
Evaluating business opportunities with retina accounts
Engagement and financial management decisions
Gaps in field educational resources
Scaling financial processes for growth
Aligning financial planning with strategy

▲Active Projects

Launch of new product in geographic atrophy
Practice-specific strategic plan for retina accounts
Pipeline advancement and lifecycle management for upcoming launches
Continuous process verification
Process implementation and validation
Design and populate eibs for key workday processes
Hris system upgrades and migrations
2025 product launch
Patient advocacy focus groups
Ophthalmology program support

Hiring Activity

Steady50 roles · 20 in 30d

Department

Sales

16

HR

6

Healthcare

5

Marketing

5

Finance

3

Medical

3

Data

2

Manufacturing

2

Seniority

Senior

16

Director

12

Mid

10

Manager

6

Junior

1

VP

1

Notable leadership hires: Brand Lead, Medical Director, Executive Director

Company intelligence

Find more companies like Apellis Pharmaceuticals by tech stack, pain points and active projects

Get started free

About Apellis Pharmaceuticals

Apellis develops complement-targeted therapies focused on C3, a single target in the complement cascade that addresses multiple immune-pathway disease drivers. The company maintains active clinical and commercial programs across ophthalmology (geographic atrophy), nephrology, hematology (paroxysmal nocturnal hemoglobinuria, cold agglutinin disease), and neurology, with product launches underway in the United States and Germany. As a public company with 501–1,000 employees headquartered in Waltham, Massachusetts, Apellis operates across the full pharma stack: research and development, regulatory affairs, manufacturing, patient advocacy, and commercial field operations.

HeadquartersWaltham, MA

Company Size501–1,000 employees

Founded2008

Hiring MarketsUnited States, Australia, Germany, Switzerland

Frequently Asked Questions

What is Apellis Pharmaceuticals' main technology focus?

Apellis targets C3 in the complement cascade—the only single target addressing all three disease-driving pathways. The platform is applied across ophthalmology, nephrology, hematology, and neurology indications.

What countries is Apellis hiring in?

Apellis is recruiting across the United States, Australia, Germany, and Switzerland, with Germany-specific hiring aligned to their first-product launch in that market.